0
Please log in or register to do it.

Huons logo

Huons logo

(Seoul = Larose.VIP) Reporter Cho Hyun-young = Huons[243070]announced that it recorded an operating profit of 55 billion won on a consolidated basis last year, a 35% increase compared to the year before.

Sales increased 12% over the same period to 552 billion won. Both sales and operating profit are the highest ever.

In the fourth quarter of last year, sales increased 12% from the previous year to KRW 145.2 billion, but operating profit decreased 32% to KRW 11 billion.

Huons explained that the prescription drug division drove its highest ever performance.

Sales of prescription drugs for various disease groups, including anesthetics, circulatory system, and digestive system, increased evenly, and sales of the overall prescription drug business last year recorded 261.2 billion won, a 22% increase from the year before.

In particular, five injectable products, including lidocaine local anesthetic approved in the U.S., contributed to performance by raising exports of 26.2 billion won in the North American market.

The beauty and wellness business achieved sales of KRW 188.8 billion, up 8% from the previous year, based on the stable growth of non-reimbursement medicines such as vitamin injections and health functional food businesses.

The consignment manufacturing (CMO) business also continued its growth, recording sales of 65 billion won.

However, it was explained that operating profit in the fourth quarter decreased due to an increase in one-time sales and administrative expenses such as bonuses and initial operation costs of the second Jecheon plant.

Huons CEO Song Soo-young said, “This year, we will achieve stable growth and operating profit based on external growth by securing production lines, diversification of export products to the global market, and sound management.”

On this day, Huons announced its sales forecast for this year at KRW 635.3 billion on the Korea Exchange.

Meanwhile, as its subsidiaries, including Huons, Humedix, and Huons Biopharma, grew evenly, its holding company, Huons Global, also achieved its highest performance ever last year.

Huons Global’s sales and operating profit last year were KRW 758.4 billion and KRW 114.8 billion, respectively, up 14.2% and 32.8% from the year before.

Humedix, a subsidiary in the beauty field, recorded sales and operating profit of KRW 152.3 billion and KRW 37.3 billion, up 24% and 43% over the same period, as the market share of filler and botulinum toxin products increased.

Huons Biopharma, which is in charge of approval and clinical trials for botulinum toxin, also contributed to the strong performance, with sales of 44.3 billion won and operating profit of 14.9 billion won, up 40% and 141% from the previous year.

hyun0@yna.co.kr

Report to KakaoTalk okjebo 2024/02/14 15:40 Sent

Shin Jung inaugurated as the 34th president of Chonnam National University Hospital, “Preparing for a future-oriented smart hospital”
Xiaomi 14 Ultra Colorways Tips, Maybe...

Reactions

0
0
0
0
0
0
Already reacted for this post.

Reactions

Your email address will not be published. Required fields are marked *